Reddyrajula, Rajkumar’s team published research in European Journal of Medicinal Chemistry in 2019 | CAS: 17201-43-3

4-Cyanobenzyl bromide(cas: 17201-43-3) is an important intermediate for pharmaceutical production. It can be used for the synthesis of a series of piperidine-linked aromatic diimidazolines, which have been synthesized as conformationally restricted congeners of the anti-Pneumocystis carinii (PCP) drug, Pentamidine.Reference of 4-Cyanobenzyl bromide

The author of 《Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies》 were Reddyrajula, Rajkumar; Dalimba, Udayakumar; Madan Kumar, S.. And the article was published in European Journal of Medicinal Chemistry in 2019. Reference of 4-Cyanobenzyl bromide The author mentioned the following in the article:

The synthesis a library consisting of four sets of phenothiazine incorporated 1,2,3-triazole compounds using mol. hybridization approach. The new hybrid mols. were synthesized and screened for in-vitro growth inhibition activity against Mycobacterium tuberculosis H37Rv strain (ATCC-27294). Among the tested compounds, nineteen compounds exhibited significant activity with MIC value 1.6 μg/mL, which was two fold higher than the MIC value of standard first-line TB drug Pyrazinamide. In addition, all these compounds were proved to be non-toxic (with selective index > 40) against VERO cell lines. However, these compounds did not inhibit significantly the growth of Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa strains: the activity profile was similar to that observed for standard anti-TB drugs (isoniazid and pyrazinamide), indicating the specificity of these compounds towards the Mycobacterium tuberculosis strain. The mol. docking studies against two target enzymes (Inh A and CYP121) to further validate the antitubercular potency of these mols. was reported. Furthermore, prediction of in silico-ADME and pharmacokinetic parameters indicated that these compounds were good oral bioavailability. The results suggested that these phenothiazine incorporated 1,2,3-triazole compounds were a promising class of mol. entities for the development of new antitubercular leads.4-Cyanobenzyl bromide(cas: 17201-43-3Reference of 4-Cyanobenzyl bromide) was used in this study.

4-Cyanobenzyl bromide(cas: 17201-43-3) is an important intermediate for pharmaceutical production. It can be used for the synthesis of a series of piperidine-linked aromatic diimidazolines, which have been synthesized as conformationally restricted congeners of the anti-Pneumocystis carinii (PCP) drug, Pentamidine.Reference of 4-Cyanobenzyl bromide

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts